Informed consent and immunohistochemistry screening for Lynch syndrome

Genetics in Medicine

Volumn 13, Issue 9, 2011, Pages 848-849

  Williams, Janet L ^a   Williams, Marc S ^a  

^a INTERMOUNTAIN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CANCER SCREENING; COWDEN SYNDROME; DNA SEQUENCE; ETHICS; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; LETTER; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PATIENT EDUCATION; STAINING; THYROID CANCER;

EID: 80052567299     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1097/GIM.0b013e318228efc8     Document Type: Letter

References (4)

1. Chubak B, Heald B, Sharp RR. Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome. Genet Med 2011; 13:356-360.
2. EGAPP Working Group. Recommendations for the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality form Lynch syndrome in relatives. Genet Med 2009;11:35-41.
3. Bao F, Panarelli NC, Rennert H, Sherr DL, Yantiss RK. Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma. Am J Surg Pathol 2010;34:1798-1804.
4. Sinicrope FA, Yang ZJ. Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer. Future Oncol 2011;7:467-474.